Ambroxol/Erdosteine

氨溴索/厄多司坦

Report date: 2022/09/09 17:32:02

Base Information

Drug NameAmbroxol/Erdosteine
Drug Alias Name厄多司坦/氨溴索Erdosteine/Ambroxol厄多司坦+氨溴索Erdosteine+AmbroxolAmbroxol+Erdosteine +[6] 
ClassificationSmall molecules
Mechanisms of ActionGlycoproteins inhibitorsSodium channel alpha subunit blockers
TargetsGlycoproteinsSodium channel alpha subunit
Therapy Area/IndicationsAsthmaBronchitis, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes Ambroxol HydrochlorideErdosteine
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesJiangsu Hengrui Medicine Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJiangsu Hengrui Medicine Co Ltd
Active IndicationsN/A
Inactive IndicationsAsthmaBronchitis, Chronic

Other Information

ATC CodeN/A
Related LinksN/A